Stockscreener 앱 받기
189.28
1.99%
-3.84
시간 외 거래:
189.95
0.67
+0.35%
전일 마감가:
$193.12
열려 있는:
$189.95
하루 거래량:
1.97M
Relative Volume:
1.00
시가총액:
$293.55B
수익:
$60.48B
순이익/손실:
$10.40B
주가수익비율:
56.85
EPS:
3.3297
순현금흐름:
$8.05B
1주 성능:
+2.95%
1개월 성능:
+4.26%
6개월 성능:
+101.34%
1년 성능:
+170.32%
1일 변동 폭
$188.66
$191.48
1주일 범위
$186.24
$196.41
52주 변동 폭
$68.61
$212.71
아스트라제네카 ADR Stock (AZN) Company Profile
Compare AZN vs LLY, JNJ, ABBV, MRK, NVS
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AZN
Astrazeneca Plc
|
189.28 | 299.51B | 60.48B | 10.40B | 8.05B | 3.3297 |
LLY
Lilly Eli Co
|
1,215.83 | 1.10T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
263.40 | 643.30B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
252.74 | 449.91B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
125.99 | 318.26B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
155.17 | 299.63B | 54.66B | 13.58B | 16.05B | 7.0171 |
아스트라제네카 ADR Stock (AZN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-27 | 개시 | Citigroup | Buy |
| 2025-10-27 | 재개 | Jefferies | Buy |
| 2025-10-16 | 다운그레이드 | Deutsche Bank | Hold → Sell |
| 2025-04-15 | 개시 | Exane BNP Paribas | Outperform |
| 2025-02-13 | 업그레이드 | UBS | Neutral → Buy |
| 2025-02-12 | 개시 | Morgan Stanley | Overweight |
| 2024-11-20 | 업그레이드 | UBS | Sell → Neutral |
| 2024-11-06 | 업그레이드 | Deutsche Bank | Sell → Hold |
| 2024-09-13 | 다운그레이드 | Deutsche Bank | Hold → Sell |
| 2024-05-30 | 개시 | Goldman | Buy |
| 2024-04-16 | 업그레이드 | Deutsche Bank | Sell → Hold |
| 2024-02-08 | 다운그레이드 | Deutsche Bank | Hold → Sell |
| 2024-01-23 | 개시 | Morgan Stanley | Overweight |
| 2024-01-16 | 재개 | UBS | Sell |
| 2024-01-03 | 다운그레이드 | Jefferies | Buy → Hold |
| 2023-12-18 | 개시 | HSBC Securities | Buy |
| 2023-09-25 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-07-12 | 업그레이드 | UBS | Neutral → Buy |
| 2023-07-05 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2023-04-11 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2023-01-05 | 개시 | BMO Capital Markets | Outperform |
| 2022-09-15 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2022-09-07 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-29 | 업그레이드 | Argus | Hold → Buy |
| 2022-06-14 | 다운그레이드 | UBS | Buy → Neutral |
| 2022-02-11 | 업그레이드 | DZ Bank | Sell → Hold |
| 2021-12-07 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-08-12 | 재개 | JP Morgan | Overweight |
| 2021-04-12 | 다운그레이드 | Argus | Buy → Hold |
| 2021-03-16 | 업그레이드 | Jefferies | Hold → Buy |
| 2021-02-25 | 업그레이드 | UBS | Neutral → Buy |
| 2021-01-15 | 개시 | Deutsche Bank | Buy |
| 2020-12-07 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-30 | 업그레이드 | UBS | Sell → Neutral |
| 2020-11-11 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2020-09-29 | 개시 | Berenberg | Buy |
| 2019-11-22 | 개시 | SVB Leerink | Outperform |
| 2019-10-25 | 업그레이드 | Liberum | Hold → Buy |
| 2019-04-02 | 다운그레이드 | UBS | Neutral → Sell |
| 2019-02-05 | 개시 | Exane BNP Paribas | Outperform |
| 2019-01-25 | 업그레이드 | Shore Capital | Hold → Buy |
| 2018-12-11 | 재개 | Jefferies | Hold |
| 2018-10-09 | 개시 | Guggenheim | Buy |
| 2018-08-16 | 다운그레이드 | Jefferies | Buy → Hold |
| 2018-03-19 | 업그레이드 | Jefferies | Hold → Buy |
| 2018-02-06 | 재확인 | Leerink Partners | Mkt Perform |
| 2018-02-05 | 재확인 | Bernstein | Outperform |
| 2018-01-18 | 재확인 | Leerink Partners | Mkt Perform |
| 2017-12-29 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2017-10-16 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2017-09-25 | 업그레이드 | Exane BNP Paribas | Neutral → Outperform |
| 2017-09-22 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
모두보기
아스트라제네카 ADR 주식(AZN)의 최신 뉴스
AstraZeneca Employee Traded On Icosavax Deal, SEC Says - Law360
AstraZeneca (AZN) Receives FDA Orphan Designation for Kidney Dis - GuruFocus
AstraZeneca (AZN) officer receives share grant via incentive plan - Stock Titan
Astrazeneca nabs PDE3/4 inhibitor for COPD in $2.1B Sino deal - BioWorld News
AstraZeneca, GSK intensify China ties with Sino Biopharm deals - BioPharma Dive
Sino Biopharma Accelerates Global Growth With GSK, AstraZeneca Partnerships - Benzinga
AstraZeneca, Daiichi near UK pricing deal for breast cancer drug, Bloomberg News reports - Reuters
PRESS: AstraZeneca and Daiichi near UK Enhertu price dealBloomberg - London South East
AstraZeneca PLC outlines long-term growth drivers. Investors weigh its global drug portfolio - AD HOC NEWS
AstraZeneca, Daiichi Near UK Price Deal for Breast Cancer Drug - Bloomberg.com
AstraZeneca Gains SBP’s PDE3/4 Inhibitor To Bolster COPD Inhalant Portfolio - insights.citeline.com
AstraZeneca updates pipeline strategy as global demand for innovative medicines stays strong - AD HOC NEWS
Sino Biopharm signs AstraZeneca licensing deal, expands GSK tie-up; shares up - Investing.com Nigeria
AstraZeneca stock stays centered on business context. - AD HOC NEWS
AstraZeneca to pay $200M upfront for Sino Biopharmaceutical’s COPD drug license deal - Seeking Alpha
Hong Kong-listed Sino Biopharma, AstraZeneca sign respiratory drug deal worth up to $1.9 billion - Reuters
AstraZeneca in China experimental COPD drug deal; upfront payment $200 million - marketscreener.com
Equity Income Trust's AstraZeneca PLC(AZN) Holding History - GuruFocus
AstraZeneca focuses on long-term growth as global healthcare demand expands - AD HOC NEWS
Physicians and Patients Agree Lupus Care Is Improving, But Both Say Meaningful Gaps Remain - GlobeNewswire Inc.
Astrazeneca returns to tap China’s CSPC in $1.7B discovery deal - BioWorld News
AstraZeneca developing PP blister packaging for future drugs - Plastics News
Pfizer or AstraZeneca: Which Stock Offers Better Long-Term Potential? - Yahoo Finance
AstraZeneca operations context for US investors - AD HOC NEWS
AstraZeneca stock follows its core pipeline and US listing - AD HOC NEWS
AstraZeneca plc outlook for long-term investors - AD HOC NEWS
AstraZeneca PLC (AZN) Discusses Progress in Sustainability Strategy and the Role of AI in Healthcare InnovationSlideshow (NYSE:AZN) 2026-07-06 - Seeking Alpha
AstraZeneca PLC stock and its global pipeline. Investor focus on long-term growth - AD HOC NEWS
AstraZeneca falls Monday, underperforms market - MarketWatch
AstraZeneca PLC Stock (AZN) Moved Down by 3.79% on Jul 6: What Signal Does It Send? - TradingKey
Citi keeps AstraZeneca on 'buy' ahead of second-quarter results - Proactive financial news
ASTRAZENECA : Receives a Buy rating from Bernstein - marketscreener.com
Abbisko, AstraZeneca Team Up on Lung Cancer Drug Combo After China Trial Clearance - Yahoo Finance
AstraZeneca (AZN) Partners with CSPC on Kidney Disease Treatments Worth $1.77B - GuruFocus
AstraZeneca PLC Surges as EU Backs Key Cancer Drugs - timothysykes.com
AZN Stock Quote Price and Forecast - CNN
AstraZeneca - Encyclopedia Britannica
AstraZeneca share price edges higher on Enhertu drug gains cancer treatment approval. What are analysts forecasting? - The Twelfth Magpie
AZNAstrazeneca plc Latest SEC Filings - Finviz
AstraZeneca PLC (AZN) stock price, news, quote and history - Yahoo Finance UK
AstraZeneca and Abbisko collaborate on NSCLC combination therapy trial - Clinical Trials Arena
AstraZeneca PLC (AZN) Stock Up 6.1% but GF Value Says Overvalued -- GF Score: 76/100 - GuruFocus
AstraZeneca Rallies as Recent Oncology Approval and Pipeline Optimism Lift Sentiment - Quiver Quantitative
London Shares Flash Green; AstraZeneca Rises on Deal with Chinese Pharma Group - Yahoo Finance UK
AstraZeneca PLC Stock (AZN) Moved Up by 3.92% on Jul 2: What Signal Does It Send? - TradingKey
AstraZeneca inks kidney therapy deal worth up to $1.77B with China’s CSPC - Seeking Alpha
AstraZeneca Collaborating With CSPC Pharma in siRNA Drug Deal Worth Up to $1.77 Billion - marketscreener.com
AstraZeneca signs CSPC China deal for experimental kidney disease drugs - Reuters
CAMBIAR INVESTORS LLC's AstraZeneca PLC(AZN) Holding History - GuruFocus
China's CSPC Pharmaceutical Group to partner with AstraZeneca for renal disease drug - marketscreener.com
Abbisko and AstraZeneca partner on lung cancer trial - grafa.com
아스트라제네카 ADR (AZN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.18%
자본화:
|
볼륨(24시간):